MCID: CRY014
MIFTS: 48

Cryptococcal Meningitis

Categories: Neuronal diseases

Aliases & Classifications for Cryptococcal Meningitis

MalaCards integrated aliases for Cryptococcal Meningitis:

Name: Cryptococcal Meningitis 12 15 17
Meningitis, Cryptococcal 43 71
Meningitis Cryptococcal 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0080159
MeSH 43 D016919
UMLS 71 C0085436

Summaries for Cryptococcal Meningitis

Disease Ontology : 12 A fungal meningitis that has material basis in Crypococcus fungal infection.

MalaCards based summary : Cryptococcal Meningitis, also known as meningitis, cryptococcal, is related to meningitis and acquired immunodeficiency syndrome. An important gene associated with Cryptococcal Meningitis is ADA (Adenosine Deaminase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Amphotericin B and Lamivudine have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and brain, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Cryptococcosis, is a potentially fatal fungal disease. It is caused by one of two species; Cryptococcus... more...

Related Diseases for Cryptococcal Meningitis

Diseases related to Cryptococcal Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 412)
# Related Disease Score Top Affiliating Genes
1 meningitis 32.4 VEGFA MBL2 IFNG CSF2 ADA
2 acquired immunodeficiency syndrome 31.3 IFNG CSF2 CD4 ADA
3 bacterial meningitis 30.6 MBL2 IFNG CSF2
4 human immunodeficiency virus type 1 30.5 SRC MAPK10 IFNG CD4 ADA
5 pulmonary tuberculosis 30.5 MBL2 IFNG ADA
6 neuroretinitis 30.4 IFNG CD4
7 choroiditis 30.3 VEGFA IFNG CD4
8 meningoencephalitis 30.3 PLB1 CD8A CD4
9 sarcoidosis 1 30.3 IFNG CD8A CD4 ADA
10 immune deficiency disease 30.2 TNFSF13B TNFRSF13B MBL2 IFNG CSF2 CD4
11 nervous system disease 30.2 VEGFA IFNG CSF2 CD4
12 cryptococcosis 30.2 PLB1 MBL2 IFNG CSF2 CD8A CD4
13 anemia, autoimmune hemolytic 30.1 TNFSF13B CD8A CD4
14 hypersplenism 30.1 IFNG CSF2 CD4
15 histoplasmosis 30.0 IFNG CD8A CD4
16 pneumonia 30.0 VEGFA MBL2 IFNG CSF2 CD8A
17 extrapulmonary tuberculosis 29.9 MBL2 IFNG CD4 ADA
18 bacterial infectious disease 29.9 MBL2 IFNG CSF2 CD8A CD4
19 lung disease 29.8 VEGFA MBL2 IFNG CSF2 CD8A
20 thrombocytopenia 29.8 TNFSF13B TNFRSF13B SRC IFNG FCGR2B CSF2
21 central nervous system vasculitis 29.8 IFNG CD8A CD4
22 chronic mucocutaneous candidiasis 29.7 IFNG CSF2 CD8A CD4
23 exanthem 29.7 VEGFA CSF2 CD8A CD4
24 cryptosporidiosis 29.7 MBL2 CD8A CD4
25 arthritis 29.7 VEGFA TNFSF13B TNFSF13 IFNG CSF2
26 macroglobulinemia 29.7 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B
27 bacterial pneumonia 29.6 CD8A CD4 ADA
28 miliary tuberculosis 29.6 IFNG CD8A CD4 ADA
29 chickenpox 29.6 IFNG CD8A CD4 ADA
30 pancytopenia 29.5 IFNG CSF2 CD8A CD4
31 neurosarcoidosis 29.4 CD8A CD4
32 opportunistic mycosis 29.2 PLB1 IFNG CSF2 CD8A CD4
33 pulmonary disease, chronic obstructive 29.2 SRC CSF2 CD8A CD4
34 pneumocystosis 29.0 CD8A CD4 CARTPT
35 syphilis 29.0 CD8A CD4 CARTPT
36 connective tissue disease 28.9 VEGFA TNFSF13B TNFSF13 IFNG CD8A CD4
37 fungal meningitis 28.8 PLB1 IFNG CSF2 CD8A CD4 CARTPT
38 multiple sclerosis 28.8 TNFSF13B TNFRSF13C MBL2 IFNG CSF2 CD8A
39 malaria 28.7 VEGFA TNFSF13B MBL2 IFNG FCGR2B CSF2
40 cytomegalovirus retinitis 28.6 IFNG CSF2 CD8A CD4 CARTPT
41 rheumatoid arthritis 28.5 VEGFA TNFSF13B TNFSF13 TNFRSF13C MBL2 IFNG
42 human immunodeficiency virus infectious disease 28.2 MBL2 IFNG CSF2 CD8A CD4 CARTPT
43 systemic lupus erythematosus 27.8 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
44 leukemia, chronic lymphocytic 26.6 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
45 myeloma, multiple 26.5 VEGFA TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SRC
46 aids - neurological complications 11.5
47 intracranial hypertension 10.7
48 hydrocephalus 10.7
49 tuberculous meningitis 10.5
50 headache 10.5

Comorbidity relations with Cryptococcal Meningitis via Phenotypic Disease Network (PDN):


Acute Cystitis Cryptococcosis
Deficiency Anemia

Graphical network of the top 20 diseases related to Cryptococcal Meningitis:



Diseases related to Cryptococcal Meningitis

Symptoms & Phenotypes for Cryptococcal Meningitis

MGI Mouse Phenotypes related to Cryptococcal Meningitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.32 ADA ARRB2 CARTPT CD4 CD8A CSF2
2 immune system MP:0005387 10.25 ADA ARRB2 CARTPT CD4 CD8A CSF2
3 endocrine/exocrine gland MP:0005379 10.1 ADA CARTPT CD4 CD8A CSF2 FCGR2B
4 normal MP:0002873 9.91 ADA CD4 CD8A FCGR2B IFNG TNFRSF17
5 renal/urinary system MP:0005367 9.81 ADA CD8A CSF2 EFS FCGR2B IFNG
6 respiratory system MP:0005388 9.56 ADA ARRB2 CSF2 EFS FCGR2B IFNG
7 skeleton MP:0005390 9.28 ADA CARTPT CSF2 FCGR2B IFNG MBL2

Drugs & Therapeutics for Cryptococcal Meningitis

Drugs for Cryptococcal Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
2
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Zidovudine Approved Phase 4 30516-87-1 35370
5
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
8
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
9 Anti-Bacterial Agents Phase 4
10 Antiparasitic Agents Phase 4
11 Antiprotozoal Agents Phase 4
12 Liposomal amphotericin B Phase 4
13 Cytochrome P-450 CYP3A Inducers Phase 4
14 Reverse Transcriptase Inhibitors Phase 4
15 Anti-HIV Agents Phase 4
16 Anti-Retroviral Agents Phase 4
17 Antiviral Agents Phase 4
18 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
19 Liver Extracts Phase 4
20
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
21
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
24
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
25
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
26
Sertraline Approved Phase 3 79617-96-2 68617
27 Cyclooxygenase Inhibitors Phase 3
28 Anti-Inflammatory Agents, Non-Steroidal Phase 3
29 Analgesics, Non-Narcotic Phase 3
30 Cyclooxygenase 2 Inhibitors Phase 3
31 Antirheumatic Agents Phase 3
32 Analgesics Phase 3
33 Gastrointestinal Agents Phase 3
34 Antiemetics Phase 3
35
protease inhibitors Phase 3
36 BB 1101 Phase 3
37 Anti-Inflammatory Agents Phase 3
38 Autonomic Agents Phase 3
39 HIV Protease Inhibitors Phase 3
40 Antineoplastic Agents, Hormonal Phase 3
41 glucocorticoids Phase 3
42 Antitubercular Agents Phase 3
43 Cytochrome P-450 Enzyme Inhibitors Phase 3
44 Hormone Antagonists Phase 3
45 Antifungal Agents Phase 3
46 Steroid Synthesis Inhibitors Phase 3
47 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
48 Hormones Phase 3
49 Serotonin Uptake Inhibitors Phase 3
50 Neurotransmitter Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
2 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
3 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
4 A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis Completed NCT00976040 Phase 4
5 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV Completed NCT01656382 Phase 4 ABLC
6 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Active, not recruiting NCT03723525 Phase 4
7 Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lumbar Punctures Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine
8 A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
9 Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis Completed NCT01802385 Phase 3 Sertraline
10 Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
11 Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo Completed NCT01589289 Phase 3
12 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
13 A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis Recruiting NCT03092817 Phase 3 Dexamethasone
14 Antifungal Treatment of Cryptococcal Meningitis Not yet recruiting NCT04140461 Phase 3 Amphotericin B;Flucytosine
15 Evaluation of CrAg Screening With Enhanced Antifungal Therapy for Asymptomatic CrAg+ Persons Not yet recruiting NCT03945448 Phase 2, Phase 3 Single dose liposomal Amphotericin and Fluconazole;Fluconazole
16 Cryptococcal Antigen Screening Plus Sertraline Terminated NCT03002012 Phase 3 Sertraline;Placebo Oral Tablet;Fluconazole
17 Dexamethasone in Cryptococcal Meningitis Completed NCT00000776 Phase 2 Flucytosine;Fluconazole;Amphotericin B;Dexamethasone
18 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Meningitis Completed NCT00012467 Phase 2 Itraconazole;Flucytosine;Fluconazole;Amphotericin B;Interferon gamma-1b
19 A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis Completed NCT03112031 Phase 2 Tamoxifen;Amphotericin B;Fluconazole
20 A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis Completed NCT00145249 Phase 2 Amphotericin B;Fluconazole
21 A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis Completed NCT00885703 Phase 1, Phase 2 Fluconazole;Amphotericin B
22 Pilot Study To Determine the Feasibility of Itraconazole for Primary Treatment and Suppression of Relapse of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00000975 Phase 2 Itraconazole
23 Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial Recruiting NCT04031833 Phase 1, Phase 2 MAT2203;Amphotericin B
24 Valganciclovir for Suppression of HHV-8 Four Weeks Prior to Initiation of cART in Patients With Disseminated Kaposi Sarcoma Compare With Standard Therapy, Its Impact on the Development of IRIS and Attributable Mortality Active, not recruiting NCT03296553 Phase 2 Valganciclovir;Antiretroviral Combinations
25 A Multicenter, Randomized Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00847678 Phase 2
26 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00324025 Phase 2 Mycograb;placebo
27 An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone Terminated NCT01562132 Phase 2 Flucytosine and fluconazole;Fluconazole
28 Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis Withdrawn NCT02908334 Phase 2 Sertraline
29 Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report From June 2015 to June 2016 Completed NCT02955862 Phase 1
30 Phase I Study to Evaluate the Safety and Tolerance of RMP-7 Administered With Amphotericin B to Patients With HIV Infection and Cryptococcal Meningitis Completed NCT00002316 Phase 1 Lobradimil;Amphotericin B
31 SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy Completed NCT00000677 Phase 1 SCH 39304
32 A Randomized Study to Evaluate the Safety and Efficacy of Liposomal Amphotericin B and Amphotericin B Deoxycholate With or Without Flucytosine Followed by Fluconazole, for the Treatment of Cryptococcal Meningitis Unknown status NCT02136030 Liposomal amphotericin B;Amphotericin B-deoxycholate
33 Evaluation of a Public Health Strategy to Improve Survival of HIV Infected Patients Unknown status NCT02334670 Fluconazole
34 Vietnam Cryptococcal Retention in Care Study (CRICS) - Version 2.1 Unknown status NCT03267407
35 A Cross-Sectional Study of HIV-Related Neurological Disorders in Ten Countries of the Asia Pacific Region Unknown status NCT00168246
36 Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002076 Fluconazole
37 Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B Completed NCT00002306 Fluconazole
38 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002305 Flucytosine;Fluconazole;Amphotericin B
39 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002075 Flucytosine;Fluconazole;Amphotericin B
40 A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002068 Fluconazole;Amphotericin B
41 Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002294 Fluconazole
42 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002074 Fluconazole;Amphotericin B
43 An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002077 Fluconazole
44 Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002040 Fluconazole
45 Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00002019 Amphotericin B, Lipid-based;Amphotericin B
46 A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. Completed NCT00002113 Flucytosine;Fluconazole
47 A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00000639 Itraconazole;Flucytosine;Fluconazole;Amphotericin B
48 Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00000708 Flucytosine;Fluconazole;Amphotericin B
49 Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. Completed NCT00830856 Fluconazole;Fixed dose - Stavudine, lamivudine and Nevirapine;Fixed dose - Stavudine, Lamivudine, Nevirapine
50 The CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa Through Early Detection and Prevention of Cryptococcal Disease Completed NCT02434172

Search NIH Clinical Center for Cryptococcal Meningitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Fluconazole
Flucytosine

Cochrane evidence based reviews: meningitis, cryptococcal

Genetic Tests for Cryptococcal Meningitis

Anatomical Context for Cryptococcal Meningitis

MalaCards organs/tissues related to Cryptococcal Meningitis:

40
Testes, T Cells, Brain, Bone, B Cells, Liver, Pituitary

Publications for Cryptococcal Meningitis

Articles related to Cryptococcal Meningitis:

(show top 50) (show all 2382)
# Title Authors PMID Year
1
Cerebrospinal fluid adenosine deaminase activity for the diagnosis of tuberculous meningitis in adults. 54 61
17333738 2006
2
Cerebrospinal fluid adenosine deaminase levels in a patient with cryptococcal meningitis. 54 61
1457651 1992
3
[Cryptococcal meningitis in patients with AIDS: combined treatment with amphotericin B and fluconazole, and high levels of adenosine deaminase in cerebrospinal fluid]. 54 61
1620927 1992
4
Neurological worsening during treatment of an immunocompetent adult with Cryptococcus neoformans meningitis. 61
31993318 2020
5
Cryptococcus gattii infection in an immunocompetent host in Greece. 61
31867171 2020
6
Cerebrospinal fluid pleocytosis in immunocompromised patients: Can it be Cryptococcus. 61
31714023 2020
7
Cryptococcal antigenemia prevalence and clinical data in HIV-infected patients from the reference centre at INI-FIOCRUZ, Rio de Janeiro, Southeast of Brazil. 61
31715053 2020
8
Cryptococcal meningitis in patients with lupus nephritis. 61
31838635 2020
9
HIV-1 CNS COMPARTMENTALIZATION AND CYTOKINE INTERPLAY IN NON-SUBTYPE B HIV-1 INFECTIONS IN NIGERIA AND MALAWI. 61
31914800 2020
10
Multidrug-resistant Klebsiella oxytoca ventriculitis, successfully treated with intraventricular tigecycline: A case report. 61
31760254 2020
11
Landscape of gene expression variation of natural isolates of Cryptococcus neoformans in response to biologically relevant stresses. 61
31860441 2020
12
Reduction of Human DNA Contamination in Clinical Cerebrospinal Fluid Specimens Improves the Sensitivity of Metagenomic Next-Generation Sequencing. 61
32002752 2020
13
Anti-Cryptococcal activity of a furanone derivative-antibiofilm and opsonophagocytic potential. 61
32037102 2020
14
Postoperative Antifungal Treatment of Pulmonary Cryptococcosis in Non-HIV-Infected and Non-Transplant-Recipient Patients: A Report of 110 Cases and Literature Review. 61
32010733 2020
15
Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm3. 61
31959112 2020
16
Multifocal cryptococcal disease in an HIV-infected patient: from diagnostic pursuit to management peculiarities. 61
31937629 2020
17
MiR-30c-5p mediates inflammatory responses and promotes microglia survival by targeting eIF2α during Cryptococcus neoformans infection. 61
31958475 2020
18
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report. 61
31964348 2020
19
Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. 61
30816418 2020
20
Impaired consciousness and decreased glucose concentration of CSF as prognostic factors in immunocompetent patients with cryptococcal meningitis. 61
31969152 2020
21
Non-occlusive ST-segment elevated myocardial infarction following the administration of liposomal amphotericin B in the treatment of cryptococcal meningitis. 61
31986219 2020
22
Human IgM inhibits the formation of Titan-like cells in Cryptococcus neoformans. 61
31988178 2020
23
Evaluation of the Biofire FilmArray meningitis/encephalitis assay for the detection of Cryptococcus neoformans/gattii. 61
31972318 2020
24
Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis. 61
31957332 2020
25
Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. 61
31699504 2020
26
Efficacy of CSF beta-D-glucan diagnostic testing for fungal meningitis: a systemic review. 61
31996446 2020
27
Cryptococcal meningitis presenting as acute flaccid paralysis: A case report. 61
31350098 2020
28
One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi. 61
31155650 2020
29
Successful treatment with corticosteroids for refractory deterioration of cryptococcal meningitis with an increasing cryptococcal antigen titer. 61
31952971 2020
30
CSF early fungicidal activity as a surrogate endpoint for cryptococcal meningitis survival in clinical trials. 61
31912875 2020
31
Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. 61
31796539 2019
32
Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. 61
31461550 2019
33
A titanic drug resistance threat in Cryptococcus neoformans. 61
31765991 2019
34
First case report of fulminant septic shock from meningococcemia associated with Cryptococcus neoformans coinfection in an immunocompetent patient. 61
31660289 2019
35
Genotypic diversity in clinical and environmental isolates of Cryptococcus neoformans from India using multilocus microsatellite and multilocus sequence typing. 61
31820495 2019
36
Basic principles of the virulence of Cryptococcus. 61
31119976 2019
37
Metataxonomics of Internal Transcribed Spacer amplicons in cerebrospinal fluid for diagnosing and genotyping of cryptococcal meningitis. 61
31856054 2019
38
Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis. 61
31584146 2019
39
B cell Compartmentalization in Blood and Cerebrospinal Fluid of HIV- Infected Ugandans with Cryptococcal Meningitis. 61
31871098 2019
40
A Rare Case of Combined Pulmonary Cryptococcosis and Cryptococcal Meningitis in Renal Allograft Recipient. 61
31988551 2019
41
Overcoming the Reticuloendothelial System Barrier to Drug Delivery with a "Don't-Eat-Us" Strategy. 61
31689086 2019
42
African ST173 Cryptococcus deuterogattii strains are commonly less susceptible to fluconazole: an unclear mechanism of resistance. 61
31711926 2019
43
Case Report: Fingolimod and Cryptococcosis: Collision of Immunomodulation with Infectious Disease. 61
31889932 2019
44
Cryptococcal Antigenemia in HIV therapy-experienced Ugandans with Virologic Failure. 61
31679007 2019
45
Predictors of hospital discharge outcome from the presenting clinical characteristics and the first cerebrospinal fluid analysis among the patients with cryptococcal meningitis. 61
31590063 2019
46
Unique clinical features of cryptococcal meningitis among Chinese patients without predisposing diseases against patients with predisposing diseases. 61
30657946 2019
47
Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study. 61
31738768 2019
48
Metataxonomics of Internal Transcribed Spacer amplicons in cerebrospinal fluid for diagnosing and genotyping of cryptococcal meningitis. 61
31764170 2019
49
Skin warts during fingolimod treatment in patients with multiple sclerosis. 61
31606603 2019
50
Efficacy of ventriculoperitoneal shunting in patients with cryptococcal meningitis with intracranial hypertension. 61
31499210 2019

Variations for Cryptococcal Meningitis

Expression for Cryptococcal Meningitis

Search GEO for disease gene expression data for Cryptococcal Meningitis.

Pathways for Cryptococcal Meningitis

Pathways related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
2
Show member pathways
13.75 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
3
Show member pathways
13.59 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
4
Show member pathways
13.48 VEGFA TNFSF13B TNFRSF17 TNFRSF13C SRC MAPK10
5
Show member pathways
13.3 YWHAG TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
6
Show member pathways
13.2 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
7
Show member pathways
13.11 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
8
Show member pathways
12.54 MAPK10 IFNG CSF2 CD8A CD4
9
Show member pathways
12.52 VEGFA SRC MAPK10 FCGR2B CSF2
10 12.26 TNFRSF13C MAPK10 CSF2 CD4
11
Show member pathways
12.26 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
12 12.17 SRC MAPK10 IFNG FCGR2B
13
Show member pathways
12.09 YWHAG TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
14 12.02 VEGFA SRC MAPK10 IFNG
15
Show member pathways
12.02 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
16 11.92 IFNG CSF2 CD8A CD4
17
Show member pathways
11.89 MAPK10 IFNG CD8A CD4
18 11.8 VEGFA TNFSF13B TNFSF13 IFNG CSF2
19 11.74 MAPK10 IFNG CSF2
20 11.73 MAPK10 IFNG CSF2
21 11.72 IFNG CD8A CD4
22 11.69 SRC CD4 ARRB2
23 11.68 IFNG CSF2 CD8A CD4
24 11.66 IFNG FCGR2B CSF2
25
Show member pathways
11.66 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13B
26
Show member pathways
11.59 VEGFA IFNG CSF2
27 11.51 TNFRSF17 TNFRSF13B CD4
28 11.26 TNFRSF13B SRC CSF2
29 11.18 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13B
30 11.16 IFNG CSF2 CD4
31 11.13 TNFRSF13C TNFRSF13B CD8A CD4 ADA
32 10.8 SRC ARRB2

GO Terms for Cryptococcal Meningitis

Cellular components related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.77 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SRC PLB1
2 extracellular space GO:0005615 9.76 VEGFA TNFSF13B TNFSF13 MBL2 IFNG CSF2
3 external side of plasma membrane GO:0009897 9.02 TNFRSF13C FCGR2B CD8A CD4 ADA

Biological processes related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.02 VEGFA TNFSF13B TNFSF13 TNFRSF17 SRC MAPK10
2 positive regulation of gene expression GO:0010628 9.98 VEGFA SRC IFNG CSF2 ARRB2
3 cell surface receptor signaling pathway GO:0007166 9.91 TNFRSF13B IFNG CD8A CD4
4 adaptive immune response GO:0002250 9.89 TNFRSF17 TNFRSF13C TNFRSF13B IFNG CD4
5 positive regulation of protein phosphorylation GO:0001934 9.87 VEGFA IFNG CD4 ARRB2
6 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.78 VEGFA SRC ARRB2
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 VEGFA IFNG CSF2
8 positive regulation of T cell proliferation GO:0042102 9.75 TNFSF13B TNFRSF13C CD4
9 T cell costimulation GO:0031295 9.72 TNFSF13B TNFRSF13C SRC
10 T cell activation GO:0042110 9.71 CD8A CD4 ADA
11 immune response GO:0006955 9.7 TNFSF13B TNFSF13 IFNG FCGR2B CSF2 CD8A
12 positive regulation of phagocytosis GO:0050766 9.69 MBL2 IFNG FCGR2B
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 VEGFA SRC CD4 ARRB2
14 positive regulation of B cell proliferation GO:0030890 9.63 TNFSF13B TNFRSF13C ADA
15 positive regulation of podosome assembly GO:0071803 9.62 SRC CSF2
16 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.59 CSF2 CD4
17 regulation of circadian sleep/wake cycle, sleep GO:0045187 9.56 CSF2 ADA
18 positive regulation of interleukin-23 production GO:0032747 9.52 IFNG CSF2
19 histamine secretion GO:0001821 9.48 CSF2 ADA
20 B cell costimulation GO:0031296 9.43 TNFSF13B TNFRSF13C
21 macrophage differentiation GO:0030225 9.43 VEGFA CSF2 CD4
22 positive regulation of germinal center formation GO:0002636 9.4 TNFSF13B ADA
23 tumor necrosis factor-mediated signaling pathway GO:0033209 9.35 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
24 immune system process GO:0002376 9.23 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SRC MBL2

Molecular functions related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein domain specific binding GO:0019904 9.46 YWHAG SRC EFS ARRB2
2 cytokine activity GO:0005125 9.35 VEGFA TNFSF13B TNFSF13 IFNG CSF2
3 signaling receptor binding GO:0005102 9.1 TNFSF13B TNFSF13 SRC MBL2 CD4 ARRB2

Sources for Cryptococcal Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....